Stanford prohibits direct commercial CME sponsorship

Share this article:

Stanford University School of Medicine has announced it will prohibit “new commercial funding for specific CME courses or programs” as of September 1, 2008.

After September 1, industry funds for CME must go through Stanford's Office of Continuing Medical Education, and cannot be designated for a particular course or program, according to a Stanford newsletter. Companies may only designate funding for general categories, such as medical, pediatric and surgical specialties, diagnostic and imaging technologies and disciplines, and heath policy and disease prevention, said the newsletter.

Stanford's decision comes at the behest of the Association of American Medical Colleges (AAMC), who urged all medical schools and teaching hospitals to prohibit direct CME sponsorship last June. The AAMC recommended that schools and hospitals establish a central CME office for the coordination of industry funds, and also outlined new strictures on gifts for physicians, and detailing practices.

The New York Times reported on August 26 that Stanford would become the sixth major medical school to adopt this CME funding policy, joining the University of Massachusetts Medical School, the University of Pittsburgh School of Medicine, the University of Colorado, the University of Kansas Medical Center and the University of California Davis School of Medicine.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...